Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, December 02, 2020
Lonza has announced additional investments in its oral drug product development and manufacturing capabilities at its Tampa, Florida site.
read more
Lonza announced an expansion of its highly potent API (HPAPI) capacity for the specific support of antibody drug conjugate (ADC) payload manufacturing.
read more
Tuesday, October 09, 2018
Lonza announced an expansion of its highly potent API capacity for the specific support of antibody drug conjugate payload manufacturing.
read more
Tuesday, October 27, 2020
Lonza announced a $93m investment in its CHI Division, a dosage form delivery partner to the biopharma and health nutrition industry.
read more
Lonza has announced additional investments in its global particle engineering network for expanded capacity and specialized capabilities.
read more
Thursday, February 18, 2021
Lonza announced an expansion of its solid form selection services based at its Bend, OR (USA) site.
read more
Lonza announced an endothelial cell application center, which expands Lonza’s support for researchers.
read more
Lonza, a CDMO partner to the biopharma industry, announced the extension of its collaboration with a major biopharmaceutical partner for the commercial-scale manufacture of monoclonal antibodies, under a long-term agreement. At scale, and following ...
read more
Lonza has introduced an enhanced product line aimed at tackling concerns around bias during blinded clinical trials.
read more
Lonza expanded the range of particle engineering services offered by its Monteggio (CH) site through the introduction of X-ray powder diffraction (XRPD).
read more
Lonza announced new investments in GMP laboratories and mid-scale manufacturing assets at its API manufacturing center in Nansha, China. The investments, totaling over $22 million, will allow Lonza to provide a smoother transition from small-scale to...
read more
Wednesday, October 26, 2022
Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, announced its participation in the GENEGUT project to develop an innovative functional capsule-based delivery solution for therapies targeting ...
read more
Lonza announced its membership in the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS). Through this consortium, Lonza will collaborate with other industry leaders to advance the research and development of inhalation...
read more
Lonza announced the launch of its AI-enabled Route Scouting Service offering. The offering aims to streamline synthetic route identification for novel APIs by combining Lonza’s global chemical supply chain intelligence and in-house expertise with AI ...
read more
Lonza announced the launch of its Media Development Lab at its Singapore site. The offering aims to support bioprocessing customers in optimizing their media formulations and facilitating a smooth transition to GMP manufacturing, helping reduce scale...
read more